Therapieentscheidungen am Lebensende sind von einer besonderen Komplexität gekennzeichnet, die neben medizinischen und pflegerischen Aspekten auch ethische Abwägungen zum Beispiel bei der Formulierung der verbleibenden Therapieziele oder eines noch angemessenen Nutzen-Risiko-Verhältnisses umfasst. Palliativmedizin vermag, durch Ressourcen und Expertise belastende (und kostenträchtige) Notfalleinweisungen durch Advance Care Planning zu vermeiden als auch zu einer strukturierten Therapieentscheidung beizutragen, und hilft dadurch, Übertherapie und Kosten (Futility) am Lebensende wirksam zu vermeiden.
Therapeutic decision-making at the end of life is a highly complex process, that comprises medical and care aspects as well as ethical reasoning (for instance, about the remaining goals of care or an appropriate benefit-harm ratio). Palliative Care may avoid burdensome (and costly) emergency admissions by advance care planning and may facilitate decision making by resources and expertise in structured communication about medical decisions and may therefore contribute relevantly to avoid futile health care expenditures.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
Bharadway, P. (2016). Making the Case for Pall Care at the System Level: Outcomes Data. J Palliat Med 19 (3), 255–258.
Cartoni, C., et al. (2021). Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study. J Pall Med 24 (6), 887–893.
Elsayem, A., et al. (2004). Palliative Care Inpatient Service in a Comprehensive Cancer Center: Clinical and Financial Outcomes. J Clin Oncol 22, 2008–2014.
Gaertner, J., et al. (2017). Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. BMJ 357, j2925.
Gomes, B., et al. (2013). Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. Cochrane Database of Systematic Reviews 6.
Greer, J. A., et al. (2016). Cost Analysis of a Randomized Trial of Early Palliative Care in Patients with Metastatic Nonsmall-Cell Lung Cancer. J Pall Med 19 (8).
Hanson, L. C., et al. (2008). Clinical and Economic Impact of Palliative Care Consultation. J Pain Symptom Manage 35, 340e346.
Hasenfuß, G., et al. (2016). Initiative „Klug Entscheiden“: Gegen Unter- und Überversorgung. Dt. Ärzteblatt 113 (13), A-600 / B-506 / C-502.
Haun, M. W., et al. (2017). Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 6, CD11129.
Kaufman, B. G., et al. (2021). Cost-Effectiveness of Pall Care: Insights from the PAL-HF Trial. J Cardiac Fail 27, 662–669.
Kavalieratos, D., et al. (2016). Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA 316 (20), 2104–2114.
Kutner, J. S., et al. (2015). Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-limiting Illness. JAMA Int Med 175 (5), 691–700.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019). Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.0 (AWMF Registernummer: 128/001OL). Online unter: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/LL_Palliativmedizin_2.0_Langversion.pdf (Zugriff: 18.06.2024).
Lu, S., et al. (2024). Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer. JCO Oncol Pract 41 (16).
May, P., et al. (2015). Prospective Cohort Study of Hospital Palliative Care Teams for Inpatients With Advanced Cancer: Earlier Consultation Is Associated With Larger Cost-Saving Effect. J Clin Oncol 33, 2745–2752.
Morrison, R. S., et al. (2008). Cost Savings Associated With US Hospital Palliative Care Consultation Programs. Arch Intern Med 168 (16), 1783–1790.
Smith, T. J., and Hillner, B. E. (2011). Bending the Cost Curve in Cancer Care. N Engl J Med 364, 20–22.
Temel, J., et al. (2010). Early palliative care for patients with metastatic non small-cell lung cancer. N Engl J Med 363, 733–742.
Zhang, B., et al. (2009). Health Care Costs in the Last Week of Life – Associations With End-of-Life Conversations. Arch Intern Med 169 (5), 480–488.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 5 | 5 | 5 |
Full Text Views | 0 | 0 | 0 |
PDF Views & Downloads | 2 | 2 | 2 |
Therapieentscheidungen am Lebensende sind von einer besonderen Komplexität gekennzeichnet, die neben medizinischen und pflegerischen Aspekten auch ethische Abwägungen zum Beispiel bei der Formulierung der verbleibenden Therapieziele oder eines noch angemessenen Nutzen-Risiko-Verhältnisses umfasst. Palliativmedizin vermag, durch Ressourcen und Expertise belastende (und kostenträchtige) Notfalleinweisungen durch Advance Care Planning zu vermeiden als auch zu einer strukturierten Therapieentscheidung beizutragen, und hilft dadurch, Übertherapie und Kosten (Futility) am Lebensende wirksam zu vermeiden.
Therapeutic decision-making at the end of life is a highly complex process, that comprises medical and care aspects as well as ethical reasoning (for instance, about the remaining goals of care or an appropriate benefit-harm ratio). Palliative Care may avoid burdensome (and costly) emergency admissions by advance care planning and may facilitate decision making by resources and expertise in structured communication about medical decisions and may therefore contribute relevantly to avoid futile health care expenditures.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 5 | 5 | 5 |
Full Text Views | 0 | 0 | 0 |
PDF Views & Downloads | 2 | 2 | 2 |